Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Perspective Therapeutics, Inc.

NYSE: CATX · Life Sciences · 14 alerts · CIK 728387

Perspective Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$0.9238Close, Nov 16
Market cap
$112M
Shares outstanding
120.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Perspective Therapeutics, Inc. filings on SEC EDGAR ↗

12:05 PM ET 8-K
Clinical Trial Data

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for advanced melanoma at the SITC 2026 meeting. The data showed a 75% disease control rate at the 3.0 mCi dose level with no dose-limiting toxicities or treatment-related serious adverse events reported across 20 patients. The findings support further investigation of this targeted alpha therapy for heavily pretreated patients who have failed prior immunotherapies.

7:01 AM ET 8-K
Clinical Trial Data

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced incremental Phase 1/2a clinical trial data for [212Pb]VMT-α-NET in patients with advanced neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed a 75% progression-free survival rate at 18 months and a 47% response rate in Cohort 3, supporting plans for a Phase 3 study initiation in 2027.

10:54 AM ET 8-K
Clinical Trial Data

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.

6:28 AM ET 8-K
Regulatory Approval

Perspective Therapeutics Regulatory Approval

Perspective Therapeutics announced that the FDA has granted Fast Track Designation for PSV359, an investigational FAP-targeted alpha-particle therapy. The designation is for the treatment of adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors (SFTs).

6:20 AM ET 8-K
Research Collaboration

Perspective Therapeutics Research Collaboration with Merck

Perspective Therapeutics has entered into a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda. The combination will be tested in an ongoing Phase 1/2a study for FAP-alpha positive solid tumors, with Perspective sponsoring the study and Merck providing pembrolizumab at no cost.

Counterparty
Merck

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.